Biomarkers are increasingly being used in all therapeutic
areas of medicine to help in the prognosis and characterization of the disease.
Biomarkers play an important role in understanding the development of chronic
human diseases and the identification of subgroups that are at increased risk
for disease. Moreover, over the years, they have been widely used in all fields
of medicine to diagnose a particular disease. The increasing focus on
biomarkers is expected to increase the demand for biomarker research services
in the development and validation of new biomarkers.
Various contract research organizations provide biomarker
research services for the discovery, development, testing, and validation of
biomarkers. These organizations provide different types of biomarker research
services to their customers, such as commercialization, biomarker validation, research
assay optimization, verification, qualification, and biomarker discovery. Biotechnology
companies, pharmaceutical organizations, and research institutes partner or collaborate
with service providers for commercialization, validation, and development of
biomarkers, as well as companion diagnostic.
For instance, in 2019, BioIVT collaborated with the
Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium
to develop and support research to qualify promising biomarkers for improving
clinical practice, predicting therapeutic response, or diagnosing diseases. BioIVT
provides services in various countries worldwide, such as the U.S., the U.K.,
Singapore, Italy, etc. Biomarker
research services are specifically provided for the development and
validation of new biomarkers.
Companion diagnostic is a test or medical device used to
determine and validate drug applicability in a specific individual, as well as
risk, safety, and benefit from that drug. Qualified biomarkers have the ability
to deliver valuable information that can help during drug development. Furthermore,
in 2017, with an investment of US$ 215 million, the National Institutes of
Health launched Precision Medicine Initiative to accelerate biomedical research
and offer new tools to select therapies that can be used in a more
individualized approach with patients.
Comments
Post a Comment